贵州百灵董事长被立案后致信全体同事

Core Viewpoint - Guizhou BaiLing's chairman Jiang Wei is under investigation by the China Securities Regulatory Commission (CSRC) for suspected insider trading, prompting the company to reassure employees about its operational stability and ongoing development [1][4]. Company Operations - Jiang Wei expressed confidence in the CSRC's investigation process and urged employees to remain calm and focused on their work as the company approaches its 30th anniversary in 2024 [2][6]. - Guizhou BaiLing has achieved over 4 billion yuan in annual revenue and has contributed more than 7 billion yuan in taxes over its 30 years, providing over 6,000 jobs and aiding in poverty alleviation for over 100,000 farmers [2][6]. Financial Performance - In the first three quarters of 2025, Guizhou BaiLing reported revenues of 2.102 billion yuan and a net profit attributable to shareholders of 56.8144 million yuan, with a significant increase in operating cash flow to 536 million yuan [2][6]. Research and Development - The company is focusing on major clinical needs such as metabolic diseases and malignant tumors, with ongoing research yielding results [3][7]. - Recently, Guizhou BaiLing received approval for clinical trials of its diabetes treatment, and a key phase III trial for a lymphoma treatment has been successfully initiated, with potential market value exceeding 10 billion yuan [3][7].